# Investigational Use of Erenumab for the Treatment of Fibromyalgia Pain

> **NCT06411067** · PHASE3 · WITHDRAWN · sponsor: **United States Naval Medical Center, Portsmouth**

## Conditions studied

- Fibromyalgia

## Interventions

- **DRUG:** Erenumab
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT06411067
- **Lead sponsor:** United States Naval Medical Center, Portsmouth
- **Sponsor class:** FED
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-02-26
- **Primary completion:** 2022-05-09
- **Final completion:** 2022-05-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lapse in IRB approval
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06411067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06411067, "Investigational Use of Erenumab for the Treatment of Fibromyalgia Pain". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06411067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*